TRVI Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Trevi Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.25 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.97 |
| Beta | 1.01 |
| 11 Month Change | 22.64% |
| 3 Month Change | 16.91% |
| 1 Year Change | 41.92% |
| 33 Year Change | 71.05% |
| 5 Year Change | -34.87% |
| Change since IPO | -58.81% |
Recent News & Updates
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
May 24
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
Jan 27Recent updates
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth
May 24Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans
Jan 27Trevi adds 19% on full data set from mid-stage cough study
Sep 19Trevi Therapeutics: Moving Forward
Sep 11Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?
Mar 23Trevi has a new development chief
Feb 01Shareholder Returns
| TRVI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 16.9% | -0.6% | -0.6% |
| 1Y | 41.9% | 17.9% | 17.3% |
Return vs Industry: TRVI exceeded the US Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: TRVI exceeded the US Market which returned 17.5% over the past year.
Price Volatility
| TRVI volatility | |
|---|---|
| TRVI Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRVI has not had significant price volatility in the past 3 months.
Volatility Over Time: TRVI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 25 | Jennifer Good | www.trevitherapeutics.com |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.
Trevi Therapeutics, Inc. Fundamentals Summary
| TRVI fundamental statistics | |
|---|---|
| Market cap | US$223.28m |
| Earnings (TTM) | -US$33.57m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.8x
P/E RatioIs TRVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRVI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$33.57m |
| Earnings | -US$33.57m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TRVI perform over the long term?
See historical performance and comparison